Navigation Links
A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
Date:8/30/2007

3 mg/kg on two consecutive days immediately prior to the cisplatin administration. Treatment was for six weeks and was continued until dose limiting toxicity or disease progression.

In this trial, as measured using the RECIST criteria, in the cisplatin arm there were six partial responders, nine patients with stabilized disease and six patients who had disease progression; in the paclitaxel arm, there was one complete responder, two partial responders, eleven with stabilized disease and five patients who had disease progression. For more information about RECIST, visit http://www.recist.com. There were few side effects associated with phenoxodiol, but, as with any investigational drug, there is a possibility of unexpected side effects.

Women who are interested in participating in the OVATURE trial, or who simply wish to learn more about this study should visit http://www.OVATUREtrial.com.

(1) Piura B and Meirovitz M. Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma. Eur J Gynaecol Oncol. 2005;26(4):386-90.

About Phenoxodiol

Phenoxodiol is believed to help chemotherapy drugs, such as carboplatin, kill chemoresistant cancer cells by removing factors in the cells that block the killing action of chemotherapy.

Phenoxodiol appears to selectively inhibit the pro-survival regulator in cancer cells known as S-1-P (sphingosine-1-phosphate) that is over expressed in cancer. In response to Phenoxodiol, the S-1-P content in cancer cells is decreased rendering those cells more sensitive to chemotherapy. Indeed, in laboratory studies, it has been demonstrated that cancer cells pre-treated with phenoxodiol were killed with lower doses of chemotherapy drugs.

Importantly, phenoxodiol has been shown not to adversely affect normal cells in animal and laboratory t
'/>"/>

SOURCE Marshall Edwards Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 Professional ... in paediatric medicine by awarding the three best ... Formulation initiative (EuPFI) conference . The Formulating ... – 18 in Athens, Greece ... pharmacy students and professionals, from which three winners ...
(Date:8/21/2014)... , Aug. 21, 2014   Royal ... PHIA) today announced it has received 510(k) clearance ... market its precision planning application for Transcatheter Aortic-Valve ... TAVI application provides interventionalists with pre-procedural, high-precision positioning ... Philips TAVI planning application is available as part ...
(Date:8/21/2014)... JOSE, Calif. , Aug. 21, 2014  SI-BONE, ... medical device company that pioneered the use of the ... (MIS) device indicated for fusion of the sacroiliac (SI) ... ) published an update to its Lumbar Fusion Medical ... SI joint fusion procedure.  The policy states that the ...
Breaking Medicine Technology:Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... KVM Switches to be First Units to Sport New ... ... ATEN Technology, Inc., an,innovator of high-quality KVM (keyboard/video/mouse) and remote,connectivity ... the first LCD KVM switches to feature,product-protected antimicrobial nanocoating. The ...
... LA JOLLA, Calif., Sept. 10 TorreyPines,Therapeutics, Inc. ... its third,Phase I clinical trial for NGX267, in ... with schizophrenia (CIAS). The,compound, a functionally selective muscarinic ... when given orally to healthy male volunteers,once-daily for ...
Cached Medicine Technology:Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces 2Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces 3Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces 4TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia 2TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia 3
(Date:8/21/2014)... (PRWEB) August 21, 2014 Transvaginal ... Bard, Inc. continue to move forward in the ... Southern District of West Virginia, Bernstein Liebhard LLP ... August 14th, the Court has established new stipulated ... special handling, division, storage and preservation. (In re ...
(Date:8/21/2014)... care physicians in rural communities do not routinely ... to Penn State medical and public health researchers. ... have limited resources if they seek help., "Rural ... women," said Jennifer S. McCall-Hosenfeld, a primary care ... health sciences, Penn State College of Medicine. "However, ...
(Date:8/21/2014)... London, UK (PRWEB) August 21, 2014 ... from USD 15.6 billion in 2014 and reach USD ... during the forecast period. The drivers of such growth ... products, rising obese and diabetic population, and surging ageing ... costs of state-of-the-art wound care products. Region-wise, North America ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Lauren Collura, a ... the 2014 “Back to the Boardwalk” Facebook sweepstakes. Lauren, her ... a beautiful four-bedroom beachfront house in Lavallette beginning this Saturday. ... to the Boardwalk” sweepstakes. Last year, Horizon Blue Cross Blue ... communities after Superstorm Sandy and decided to make it a ...
(Date:8/21/2014)... THURSDAY, Aug. 21, 2014 (HealthDay News) -- In a ... that pregnant women avoid eating tuna due to concerns ... tuna, which is second only to shrimp as the ... encourage pregnant women to avoid all tuna," Jean Halloran, ... advocacy division of Consumer Reports, said in a news ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 3Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 3Health News:Consumer Reports Advises Pregnant Women to Avoid Tuna 2
... Nov. 5 Attorneys from Dallas, Rasansky Law Firm ... court on behalf of the mother of a 2-year-old girl who ... year ago. The lawsuit includes claims that the day care,s owners ... the child,s death from showing up on a state licensing database. ...
... is pleased to announce their standing in the latest ... quick, confidential performance ratings and comparisons of technology vendors, ... overall in their Q3 2009 Customer Satisfaction Industry Report. ... customer satisfaction score was the lowest ever reported by ...
... FRANCISCO, Nov. 5 Quantros, Inc., an industry leader ... point of care data surveillance solutions, today announced the ... ), a publicly traded company spun off from Cardinal ... were not disclosed. , This latest addition to ...
... Investments to ... ... nonprofit venture capital firm that invests in entrepreneurs who are building businesses to serve the ... Hill Eye and Laser Centre (UHEAL) in Kenya, both of which provide advanced eye care ...
... study finds, , THURSDAY, Nov. 5 (HealthDay News) -- What ... a good night,s sleep come more easily. , A study ... the odds of having disturbed sleep in the seven years ... years before they stopped working. , Sleep improvements probably had ...
... , WATSONVILLE, Calif., Nov. 5 Nordic Naturals ... especially for pregnant women to ensure adequate DHA, an ... for the new mother and developing baby. Prenatal DHA ... the leading non-profit organization in the United States that ...
Cached Medicine News:Health News:The Rasansky Law Firm Announces Dallas Day Care Death Lawsuit; State Investigation Finds Evidence of Negligence at Woodbridge Day School 2Health News:ChemSW Rated Top Vendor Overall for Customer Satisfaction in Q3 2009 by VendorRate 2Health News:Quantros Acquires MediQual(TM) From CareFusion Corporation 2Health News:Quantros Acquires MediQual(TM) From CareFusion Corporation 3Health News:Acumen Fund Announces Two Investments Providing Advanced Eye Care Services in India and Kenya 2Health News:Acumen Fund Announces Two Investments Providing Advanced Eye Care Services in India and Kenya 3Health News:Acumen Fund Announces Two Investments Providing Advanced Eye Care Services in India and Kenya 4Health News:Without Job Stress, Retirees Sleep Better 2Health News:Nordic Naturals Professional Exclusive Division Introduces Prenatal DHA An Omega-3 Fatty Acid Supplement for Pregnant Women 2
... AST (GOT) powder reagent once reconstituted offers ... liquid stability to help maximize laboratory productivity, ... turnaround time. The patented technology of the ... long shelf life and stability once reconstituted ...
LCD chart display...
... are extremely delicate and if repairs are ... can easily be damaged beyond repair and ... , On the other hand, with conscientious ... have a virtually indefinite lifespan. The very ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
Medicine Products: